VERBA LEGAL's pharmaceutical and healthcare practice fulfills all legal requirements for the pharmaceutical industry, medical device producers, distributors, pharmacy networks, private medical firms, digital health entities, and leading FMCG conglomerates.
The practice excels in comprehensive legal matters concerning the distribution of pharmaceuticals, medical devices, and FMCG products, dealings with pharmaceutical assets of any type, data privacy and management, and the development of industrial compliance systems.
Our team of over 20 specialists boasts the market's most extensive industry-specific expertise.
Among our clientele are more than 80% of the largest international and Russian pharmaceutical companies. They supply over 50% of the Russian pharmaceutical market. Our experts have implemented over 1,000 projects for industrial clients in the last few years.
Our practice ranks in band 1 of the Pravo-300 rating. Our attorneys are acknowledged in individual rankings such as Pravo-300, Chambers Europe, and Best Lawyers.
Practice leader Alexander Panov is also part of the Health Care Committee's expert council within the Federation Council.
Services
1/
Transactions with pharmaceutical assets
2/
Legal support in relation to the development of medicinal products and medical devices
3/
Legal support for pre-clinical and clinical trials of medicinal products, as well as clinical investigations of medical devices
4/
Legal assistance with commercial relations between participants of the pharmaceutical market, including matters relating to the circulation of medicinal products and medical devices
5/
Comprehensive support for digital healthcare projects (Big Data, AI, etc.)
6/
Advertising and promotion of medicinal products and medical devices
7/
Legal support for complex market access projects
8/
Support for large-scale regulatory and industry law-making projects
9/
Compliance
Selected Experience
Legal support for the full lifecycle of a COVID‑19 medicine, including structuring technology‑transfer deals, localizing production in more than 10 jurisdictions, registering the drug in over 30 jurisdictions, and concluding more than 40 agreements with foreign partners;
Structuring of more than 25 portfolio‑transfer deals of pharmaceutical products, including intellectual‑property, drug‑regulatory, applicable antitrust, and commercial‑structuring issues;
Implementation of more than 40 projects on production localization and development of a contractual model governing the relationship between the holder of the marketing authorization and intellectual‑property rights for medicinal products or medical devices and the manufacturer;
Comprehensive legal support for a project to promote pharmaceutical products in Russia and CIS countries, including development of a risk‑matrix for each target country and mitigation of those risks for each method of product promotion; the portfolio included more than 30 SKUs;
Preparation of a comprehensive practical guide on legal issues related to transfer of medical technologies for organizations engaged in healthcare‑related R&D in more than 12 jurisdictions;
Development of a commercialization model for genetic research in Russia, including the full contractual framework, designed to maximize the client’s interests and mitigate applicable risks; legal support for online stores of cosmetic products in the B2C segment and medical‑device sales in the B2B segment;
Full‑cycle preparation for the client of Russia’s largest special investment contract (6.25 billion rubles); this remains the largest SPIC concluded in the healthcare sector to date, under which the parties undertook obligations for localization and production of blood‑derived pharmaceutical products;
Implementation of projects to develop commercial policies for interaction with distributors for a number of pharmaceutical manufacturers;
Resolution of a number of complex regulatory challenges in connection with the launch of an innovative medical device on the Russian market.